Cargando…

Pharmacokinetic and pharmacodynamic analysis of fulvestrant in preclinical models of breast cancer to assess the importance of its estrogen receptor-α degrader activity in antitumor efficacy

PURPOSE: Fulvestrant is a selective estrogen receptor downregulator (SERD) that is approved for first- or second-line use as a single agent or in combination with cyclin dependent kinase or phosphatidylinositol 3-kinase inhibitors for the treatment of metastatic breast cancer. Fulvestrant exhibits e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wardell, Suzanne E., Yllanes, Alexander P., Chao, Christina A., Bae, Yeeun, Andreano, Kaitlyn J., Desautels, Taylor K., Heetderks, Kendall A., Blitzer, Jeremy T., Norris, John D., McDonnell, Donald P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2019
Materias:	Preclinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6985185/ https://www.ncbi.nlm.nih.gov/pubmed/31562570 http://dx.doi.org/10.1007/s10549-019-05454-y

Ejemplares similares

Correction to: Pharmacokinetic and pharmacodynamic analysis of fulvestrant in preclinical models of breast cancer to assess the importance of its estrogen receptor-α degrader activity in antitumor efficacy
por: Wardell, Suzanne E., et al.
Publicado: (2019)

G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer
por: Andreano, Kaitlyn J., et al.
Publicado: (2020)

Targeting mutant estrogen receptors
por: Wardell, Suzanne E, et al.
Publicado: (2019)

Modeling the novel SERD elacestrant in cultured fulvestrant-refractory HR-positive breast circulating tumor cells
por: Dubash, Taronish D., et al.
Publicado: (2023)

RAD1901: a novel, orally bioavailable selective estrogen receptor degrader that demonstrates antitumor activity in breast cancer xenograft models
por: Garner, Fiona, et al.
Publicado: (2015)

Improved pharmacokinetic and pharmacodynamic profile of a novel PEGylated native Erwinia chrysanthemi L-Asparaginase
por: Modi, Tapasvi, et al.
Publicado: (2021)

Estrogen receptor splice variants as a potential source of false-positive estrogen receptor status in breast cancer diagnostics
por: Groenendijk, Floris H., et al.
Publicado: (2013)

Investigating the role of endogenous estrogens, hormone replacement therapy, and blockade of estrogen receptor-α activity on breast metabolic signaling
por: Arnone, Alana A., et al.
Publicado: (2021)

In Pursuit of Understanding the Role of Estrogens in Regulating Cardiac Structure and Function
por: Villarreal, Francisco
Publicado: (2020)

Cardiac Versus Renal Response to Volume Expansion in Preclinical Systolic Dysfunction With PDEV Inhibition and BNP
por: Wan, Siu-Hin, et al.
Publicado: (2019)

The Effect of Estrogen on Intracellular Ca(2+) and Na(+) Regulation in Heart Failure
por: Firth, Jahn M., et al.
Publicado: (2020)

Fulvestrant: pharmacokinetics and pharmacology
por: Robertson, J F R, et al.
Publicado: (2004)

Transcatheter Tricuspid Valve Implantation of NaviGate Bioprosthesis in a Preclinical Model
por: Navia, Jose L., et al.
Publicado: (2018)

Female Authorship in Preclinical Cardiovascular Research: Temporal Trends and Influence on Experimental Design
por: Labinaz, Alisha, et al.
Publicado: (2019)

Septal Reduction Using Transvenous Intramyocardial Cerclage Radiofrequency Ablation: Preclinical Feasibility
por: Shin, Eun-Seok, et al.
Publicado: (2020)

Raptor localization predicts prognosis and tamoxifen response in estrogen receptor-positive breast cancer
por: Bostner, Josefine, et al.
Publicado: (2017)

Preclinical activity of gefitinib in non-keratinizing nasopharyngeal carcinoma cell lines and biomarkers of response
por: Ma, Brigette B.Y., et al.
Publicado: (2009)

Stress vulnerability promotes an alcohol‐prone phenotype in a preclinical model of sustained depression
por: Riga, Danai, et al.
Publicado: (2018)

Quality assessment of estrogen receptor and progesterone receptor testing in breast cancer using a tissue microarray-based approach
por: Dekker, T. J. A., et al.
Publicado: (2015)

Western Diet-Fed, Aortic-Banded Ossabaw Swine: A Preclinical Model of Cardio-Metabolic Heart Failure
por: Olver, T. Dylan, et al.
Publicado: (2019)

Activation of Akt, mTOR, and the estrogen receptor as a signature to predict tamoxifen treatment benefit
por: Bostner, Josefine, et al.
Publicado: (2012)

Antitumor activity of a rhenium (I)-diselenoether complex in experimental models of human breast cancer
por: Collery, Philippe, et al.
Publicado: (2015)

Antitumor activity of recombinant RGD-IFN-α2a-core fusion protein in vitro
por: Wen, Zhengwei, et al.
Publicado: (2017)

Anti-tumor efficacy of fulvestrant in estrogen receptor positive gastric cancer
por: Yi, Jun Ho, et al.
Publicado: (2014)

Endoxifen and fulvestrant regulate estrogen-receptor α and related DEADbox proteins
por: Asberger, Jasmin, et al.
Publicado: (2020)

Antitumor and immunomodulatory effects of a novel multitarget inhibitor, CS2164, in mouse hepatocellular carcinoma models
por: Zhou, You, et al.
Publicado: (2019)

Mitral Butterfly: Preclinical Experience of a Novel Chordal Repair Device Using an Artificial Papillary Muscle
por: Ticar, Johanna M., et al.
Publicado: (2020)

Molecular features of androgen-receptor low, estrogen receptor-negative breast cancers in the Carolina breast cancer study
por: Jinna, Nikita D., et al.
Publicado: (2023)

Estrogen Receptor-α Non-Nuclear Signaling Confers Cardioprotection and Is Essential to cGMP-PDE5 Inhibition Efficacy
por: Fukuma, Nobuaki, et al.
Publicado: (2020)

Advanced glycation end products are elevated in estrogen receptor-positive breast cancer patients, alter response to therapy, and can be targeted by lifestyle intervention
por: Walter, Katherine R., et al.
Publicado: (2018)

MYC as a therapeutic target for the treatment of triple-negative breast cancer: preclinical investigations with the novel MYC inhibitor, MYCi975
por: Tang, Minhong, et al.
Publicado: (2022)

SLC1A5 co-expression with TALDO1 associates with endocrine therapy failure in estrogen receptor-positive breast cancer
por: Alfarsi, Lutfi H., et al.
Publicado: (2021)

The Lineage Determining Factor GRHL2 Collaborates with FOXA1 to Establish a Targetable Pathway in Endocrine Therapy-Resistant Breast Cancer
por: Cocce, Kimberly J., et al.
Publicado: (2019)

Fulvestrant-Mediated Inhibition of Estrogen Receptor Signaling Slows Lung Cancer Progression
por: Tang, Hexiao, et al.
Publicado: (2014)

A prospective cohort study of clinical characteristics and outcomes in Chinese patients with estrogen receptor-negative/progesterone receptor-positive early breast cancer
por: Fan, Yu, et al.
Publicado: (2023)

Antiproliferative activity, mechanism of action and oral antitumor activity of CP-4126, a fatty acid derivative of gemcitabine, in in vitro and in vivo tumor models
por: Bergman, Andries M., et al.
Publicado: (2010)

Quantitative proteomic analysis reveals that Luks-PV exerts antitumor activity by regulating the key proteins and metabolic pathways in HepG2 cells
por: Zhao, Chang-Cheng, et al.
Publicado: (2020)

Tie2-Cre–Induced Inactivation of Non-Nuclear Estrogen Receptor-α Signaling Abrogates Estrogen Protection Against Vascular Injury
por: Liu, Pang-Yen, et al.
Publicado: (2022)

DZ-2384 has a superior preclinical profile to taxanes for the treatment of triple-negative breast cancer and is synergistic with anti-CTLA-4 immunotherapy
por: Bernier, Cynthia, et al.
Publicado: (2018)

The estrogen receptor coactivator AIB1 is a new putative prognostic biomarker in ER-positive/HER2-negative invasive lobular carcinoma of the breast
por: Narbe, Ulrik, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_j2keaavi9mi556p4mng9m0t1q9